UCLA UCLA Previously Published Works

Title

Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer.

Permalink

https://escholarship.org/uc/item/91q142wb

Journal Journal of Nuclear Medicine, 64(11)

Authors

Meyer, Catherine Stuparu, Andreea Lueckerath, Katharina <u>et al.</u>

Publication Date 2023-11-01

DOI

10.2967/jnumed.123.265433

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <u>https://creativecommons.org/licenses/by/4.0/</u>

Peer reviewed

Tandem Isotope Therapy with ²²⁵Ac- and ¹⁷⁷Lu-PSMA-617 in a Murine Model of Prostate Cancer

Catherine Meyer¹, Andreea Stuparu¹, Katharina Lueckerath^{1,2}, Jeremie Calais¹, Johannes Czernin¹, Roger Slavik¹, and Magnus Dahlbom¹

¹Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and ²Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany

Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using ¹⁷⁷Lu or ²²⁵Ac has demonstrated encouraging treatment responses; however, responses are not durable. Dual-isotope combinations, or "tandem" approaches, may improve tolerability while retaining a high tumor dose. In this study, we directly compared α- versus β-particle treatment, as well as a combination thereof, at different stages of disease in a murine model of disseminated prostate cancer. Methods: First, to determine comparable injected activities from ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617, ex vivo biodistribution studies were performed at 5 time points after treatment of C4-2 subcutaneous tumor-bearing NSG mice. To establish a more representative model of metastatic prostate cancer, NSG mice were inoculated with luciferase-expressing C4-2 cells in the left ventricle, leading to disseminated visceral and bone lesions. At either 3 or 5 wk after inoculation, the mice were treated with equivalent tumor dose-depositing activities of ¹⁷⁷Lu- or ²²⁵Ac-PSMA-617 alone or in combination (35 MBq of ¹⁷⁷Lu, 40 kBq of ²²⁵Ac, or 17 MBq of ¹⁷⁷Lu + 20 kBg ²²⁵Ac; 10/group). Disease burden was assessed by weekly bioluminescence imaging. Treatment efficacy was evaluated using whole-body tumor burden and overall survival. Results: The ex vivo biodistribution studies revealed that 35 MBg of ¹⁷⁷Lu and 40 kBg of ²²⁵Ac yield equivalent absorbed tumor doses in a subcutaneous C4-2 model. The disease burden of mice treated at 3 wk after inoculation (microscopic disease) with ¹⁷⁷Lu was not significantly different from that of untreated mice. However, $^{225}\text{Ac-PSMA-617}$ both as a single agent and in combination with ^{177}Lu (17 MBq of ^{177}Lu + 20 kBq of ²²⁵Ac) were associated with significant whole-body tumor growth retardation and survival benefit (overall survival, 8.3 wk for nontreatment, 9.4 wk for ¹⁷⁷Lu, 15.3 wk for ²²⁵Ac alone, and 14.1 wk for tandem therapy). When treated at 5 wk after inoculation (macroscopic disease), all treatment groups showed retarded tumor growth and improved survival, with no significant differences between ²²⁵Ac alone and administration of half the ²²⁵Ac activity in tandem with ¹⁷⁷Lu (overall survival, 7.9 wk for nontreatment, 10.3 wk for ¹⁷⁷Lu, 14.6 wk for ²²⁵Ac alone, and 13.2 wk for tandem therapy). Conclusion: Treatment of a disseminated model of prostate cancer with simultaneous ²²⁵Ac- and ¹⁷⁷Lu-PSMA-617 results in significantly decreased tumor growth compared with ¹⁷⁷Lu, which was ineffective as a single agent against

Received Jan. 13, 2023; revision accepted Jun. 17, 2023.

microscopic lesions. Mice treated later in the disease progression and bearing macroscopic, millimeter-sized lesions experienced significant tumor growth retardation and survival benefit in both monoisotopic and tandem regimens of ¹⁷⁷Lu and ²²⁵Ac. Although the greatest benefits were observed with the single agent ²²⁵Ac, the tandem arm experienced no significant difference in disease burden or survival benefit, suggesting that the reduced activity of ²²⁵Ac was adequately compensated in the tandem arm. The superior therapeutic efficacy of ²²⁵Ac in this model suggests a preference for α -emitters alone, or possibly in combination, in the microscopic disease setting.

Key Words: PSMA-617; ¹⁷⁷Lu; ²²⁵Ac; mouse model; prostate cancer; RLT

J Nucl Med 2023; 64:1772–1778 DOI: 10.2967/jnumed.123.265433

Radionuclide therapy targeting the prostate-specific membrane antigen (PSMA) protein is a promising option for patients with metastatic castration-resistant prostate cancer. The most commonly used therapeutic isotope is 177 Lu, a medium-energy β -emitter (0.5 MeV) with a 6.7-d half-life (1). Response rates to ¹⁷⁷Lu-PSMA-617 (as measured by >50% decline in serum biomarker prostate-specific antigen) have varied from 30% to 70% across treatment studies and patient cohorts (2-7). With a tissue penetration range of less than 2 mm and the ensuing cross-fire effect, ¹⁷⁷Lu β-particles are best suited for treating lesions of a certain size (i.e., nonmicroscopic) (8-10). Although treatment with ¹⁷⁷Lu-PSMA-617 is largely well tolerated, with a favorable dosimetry profile (11-13), in the setting of diffuse bone marrow infiltration, treatment with β -emitters may be limited by hematologic toxicity due to the irradiation of the surrounding healthy bone marrow tissues (10). ²²⁵Ac, an α -emitter with a 9.9-d half-life, has emerged as an alternative isotope with favorable therapeutic decay properties. α-particles are of interest in radionuclide therapy because of higher energy deposition over a much shorter tissue penetration range, causing more dense ionizations and localized dose profiles than for β-particles (14–16). The higher energy of ²²⁵Ac α -particles over a shorter tissue range (<0.1 mm) leads to a linear energy transfer on the order of 100 keV/µm (9,17-19). Decay schemes for ¹⁷⁷Lu and ²²⁵Ac are shown in Figure 1.

Although fewer clinical studies have been conducted with ²²⁵Ac-PSMA-617, studies so far have reported biochemical response rates (>50% decline in prostate-specific antigen) ranging from 25% to over 90%, though patient cohorts, prior treatments, and treatment settings have varied widely (20–23). Additionally, α -particle therapy may be favored in the treatment of microscopic metastatic disease and bone marrow infiltration because of the shorter range of

For correspondence or reprints, contact Magnus Dahlbom (mdahlbom@ mednet.ucla.edu).

Guest editor: David Mankoff, University of Pennsylvania

Published online Oct. 5, 2023.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

COPYRIGHT © 2023 by the Society of Nuclear Medicine and Molecular Imaging.




FIGURE 1. (A) ¹⁷⁷Lu decay scheme. (B) ²²⁵Ac decay scheme.

 α -radiation (24–27). However, the same radiobiologic features that make ²²⁵Ac attractive against tumors also present a tradeoff at the expense of higher-grade toxicities (22). The most significant adverse effect of α -particle PSMA-targeted radionuclide therapy with small molecules (i.e., PSMA-617, PSMA-I&T) is xerostomia, making the salivary glands a key dose-limiting organ (28). Although the accumulation of PSMA ligands in the salivary glands is still not well understood, it is believed to be the result of both nonspecific (non–PSMA-related) and specific (PSMA-related) uptake mechanisms of PSMA ligands (29–31). Although xerostomia from ¹⁷⁷Lu therapy is often temporary and reversible, with ²²⁵Ac there is a greater incidence of xerostomia, which can significantly diminish patient quality of life and lead to treatment discontinuation (22,32,33).

Overall, clinical experience using ¹⁷⁷Lu or ²²⁵Ac has shown encouraging treatment responses; however, the responses have not been durable. Given that salivary gland toxicity limits the injected activity of ²²⁵Ac, simply using higher ²²⁵Ac treatment activities to increase tumor dose delivery is not an option. Dual-isotope combinations, or "tandem" approaches, may provide the benefits of both ¹⁷⁷Lu and ²²⁵Ac to improve treatment tolerability while retaining high tumor dose delivery (10,34). Early clinical studies on both ¹⁷⁷Lunaïve patients and those who progressed after ¹⁷⁷Lu-PSMA have shown that augmentation of ¹⁷⁷Lu-PSMA therapy with a boost of ²²⁵Ac is an effective option with a more favorable side effects profile (35-37). No incidents of grade 3 or higher xerostomia were reported in these studies. A similar approach has been tested in peptide receptor radionuclide therapy against neuroendocrine tumors using tandem ¹⁷⁷Lu/⁹⁰Y-DOTATATE, combining 2 β-particle-emitting isotopes with different energies and tissue penetration ranges (38,39). In the preclinical setting, tandem 177Lu/90Y-DOTATATE demonstrated an antitumor effect superior to that of either monotherapy alone (40). For PSMA-targeted therapies, clinical data are still limited by small patient cohort sizes, and to date, there have been no systematic preclinical investigations into the efficacy of dual-isotope combinations. In this work, we sought to directly compare α - versus β -particle PSMA radionuclide therapy, as well as combinations of the two, in a mouse model of prostate cancer. Our hypothesis was that the emitted particle pathlength can impact the radiation dose delivery, especially to microscopic disease. The objective was to compare the treatment efficacy of a scaled combination of ²²⁵Ac and ¹⁷⁷Lu to single-isotope treatments, as measured by longitudinal tumor control and survival. First, we conducted an ex vivo γ -counting biodistribution and tumor dosimetry study to determine injected activities of ¹⁷⁷Lu and ²²⁵Ac that yield comparable tumor doses. We then treated mice bearing disseminated prostate cancer lesions at 2 different stages of disease with ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617 as single agents, or in combination, to compare therapeutic efficacy and survival.

MATERIALS AND METHODS

Cell Culture and Animal Studies

In all studies, the human-derived, PSMA-expressing prostate cancer tumor cell line C4-2 was used (courtesy of Dr. George Thalmann, Inselspital Bern, Switzerland). Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Omega Scientific) and grown at 37°C and 5% CO₂. Cells were monitored for *Mycoplasma* contamination using the Venor GeM *Mycoplasma* detection kit (Sigma Aldrich) and authenticated by short tandem repeat sequencing (Laragen). The parental cells were engineered to express firefly luciferase (C4-2-luc) to allow luciferase-mediated bioluminescence imaging to monitor tumor burden, as previously described (*41*).

All animal studies were approved by the UCLA Animal Research Committee (approval 2005-090). The mice were housed under pathogenfree conditions with food and water ad libitum and a 12 h–12 h light– dark cycle. Veterinary staff and investigators observed the mice daily to ensure animal welfare.

Radiochemistry

PSMA-617 precursor was obtained from ABX Advanced Biochemical Compounds. ¹⁷⁷Lu was obtained from Spectron MRC, and ²²⁵Ac was supplied by the U.S. Department of Energy's Isotope Program within the Office of Science. Radiolabeling was performed as previously described with molar activities of 84 GBq/µmol and 130 MBq/µmol for ¹⁷⁷Lu and ²²⁵Ac-PSMA-617, respectively (*41,42*).

Biodistribution and Tumor Dosimetry of ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617

Immunodeficient, 6- to 8-wk-old NOD SCID γ (NSG; The Jackson Laboratory) male mice were inoculated subcutaneously with 5×10^{6} C4-2 cells in 100 µL of Matrigel (Corning) into the shoulder region (50 mice). After 3 wk, when the tumors reached about 300 mm³ in volume, the mice were treated with either 30 MBq of ¹⁷⁷Lu-PSMA-617 (25 mice) or 40 kBq of ²²⁵Ac-PSMA-617 (25 mice). The treatment activities were based on efficacious and well-tolerated activities in previous studies (43). The mice were euthanized at 1, 4, 24, 48, and 168 h after treatment (5 mice per time point for each nuclide). At the time of euthanasia, tumors and organs (including kidneys, liver, submandibular salivary glands, and intestines) were collected for ex vivo γ -counting for activity quantification (177Lu energy window, 189-231 keV; 225Ac energy window, 170–260 keV for ²²¹Fr daughter detection; Cobra II Auto-Gamma; Packard Instrument Co.). Actinium samples were counted after 24 h when secular equilibrium was reached (44). The multiple t test method with Welch correction was used for biodistribution statistical comparisons (statistical significance set to ≤ 0.05).

We estimated tumor self-doses (ignoring cross-dose contributions from neighboring organs) by first curve-fitting and integrating the tumor time–activity curves (NUKFIT Software) (45). The total number of disintegrations was multiplied by dose constants to yield tumor doses for ¹⁷⁷Lu and ²²⁵Ac (5.934 × 10⁻¹ and 2.838 × 10⁻³ Gy·g/[μ Ci·h], respectively). Dose constants are derived from nuclear data for energy

released per disintegration of each radionuclide, ignoring contributions with a decay yield of less than 1% (*1*,46). In this case of self-dose calculation, it is assumed that all radiation has an absorption fraction of 1.0 and that all disintegrations measured in the tumor deposit all energy in the tumor. We could thereby estimate the injected activities of 177 Lu- and 225 Ac-PSMA-617 that yield approximately equal tumor doses for subsequent studies directly comparing single- versus dualisotope approaches.

Tandem ¹⁷⁷Lu/²²⁵Ac Therapy

All subsequent therapy studies were investigated in a mouse model of advanced metastatic prostate cancer. NSG mice were inoculated with C4-2-luc cells in the left ventricle, leading to disseminated visceral and bone lesions, as previously described (80 mice) (41). The mice were treated at 2 different stages of disease-either 3 or 5 wk after inoculation with equivalent tumor dose-depositing activities of ¹⁷⁷Lu- or ²²⁵Ac-PSMA-617 or in scaled combination. Three weeks after inoculation, the disseminated lesions are approximately 200 µm in size, increasing to millimeter scale by 5 wk, as previously characterized (41). The treatment activities were determined by the tumor biodistribution and dose-finding study as previously described. The treatment groups were as follows: 35 MBq of ¹⁷⁷Lu-PSMA-617, 40 kBq of ²²⁵Ac-PSMA-617, a mixture of 17 MBq of ¹⁷⁷Lu-PSMA-617 plus 20 kBq of ²²⁵Ac-PSMA-617, or untreated (10 mice per group per treatment time, intravenous administration; the chosen activities are justified in the Results section). The tandem-isotope treatment regimen was designed to halve the respective doses of ²²⁵Ac and ¹⁷⁷Lu in combination.

Disease burden was assessed by weekly luciferase-mediated bioluminescence imaging (IVIS Lumina III; Perkin Elmer), and the mice

were followed for overall survival. The mice were euthanized when their overall condition showed signs of deteriorating health based on the body conditioning score (47). Therapeutic efficacy data regarding tumor burden, as measured by whole-body radiance over time (Living Image; Perkin Elmer), were analyzed with 1-way ANOVA with Bonferroni adjustment using GraphPad Prism 8. The log-rank (Mantel–Cox) test was used for survival analysis.

RESULTS

Biodistribution and Tumor Dosimetry of ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617

The ex vivo biodistribution of ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617 in subcutaneous tumors and organs is shown in Figure 2. Tabulated biodistribution values for tumors and organs are available in Supplemental Tables 1 and 2 (supplemental materials are available at http://jnm.snmjournals.org). Kidney uptake at 1 h after injection was significantly greater for 225 Ac than for 177 Lu (25.9% ± 3.5% and 13.3% \pm 1.6% injected activity/g, P < 0.0005), but no statistical difference was observed at later time points. Both 177Lu- and 225Ac-PSMA-617 rapidly localized to the tumor, with similar uptake $(14.4\% \pm 4.1\% \text{ and } 14.1\% \pm 4.9\% \text{ injected})$ activity/g, respectively) at 4 h after intravenous injection (not statistically significant; P = 0.89). Tumor uptake peaked at 4 h after injection, and by 168 h (7 d), tumor uptake was significantly greater in ²²⁵Ac-treated tumors than in ¹⁷⁷Lu-treated tumors (9.3% \pm 1.3% vs. $6.3\% \pm 0.9\%$ injected activity/g, P < 0.004, 5 mice per radionuclide). Tumor time-activity uptake curves in percentage injected activity were used for curve-fitting in NUKFIT (Figs. 2B and 2D). NUKFIT software selected the best curve-fitting model in both cases to be in the following form: $A_1 e^{-\lambda_1 t} + A_2 e^{-\lambda_2 t}$, where λ_1 and λ_2 represent the fitted decay constants. The best-fit curve parameters are shown in Figure 2. The resultant cumulated activities were multiplied by the respective dose constants and normalized by injected activity and average tumor masses. The tumor-absorbed doses for 177Lu- and ²²⁵Ac-PSMA-617 in the subcutaneous C4-2 model were 0.00758 and 65.03 cGy/kBq, respectively, or roughly 850 times greater for ²²⁵Ac than for ¹⁷⁷Lu. Therefore, from this study we decided to use 35 MBq of ¹⁷⁷Lu and 40 kBq of ²²⁵Ac to yield similar absorbed tumor doses in the therapeutic efficacy studies. Previous work demonstrated that 40 kBq of ²²⁵Ac-PSMA-617 is well tolerated (43). For the tandem treatment arm, we chose to halve the activity of each isotope in combination (17 MBg of $^{177}Lu + 20$ kBg of ^{225}Ac) to test a more tolerable activity regimen.

Tandem ¹⁷⁷Lu/²²⁵Ac Therapy

Whole-body bioluminescence imaging radiance over time and mouse survival curves for treatment 3 wk after inoculation are shown in Figures 3 and 4, respectively. Notably, the disease burden of mice treated at this earlier stage of disease with ¹⁷⁷Lu-PSMA-617 was not significantly different from that of untreated mice at any time point (P = 0.932). However, ²²⁵Ac-PSMA-617




FIGURE 2. Ex vivo biodistribution and tumor time–activity curves for ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617. (A) Mean ± SD percentage injected activity per gram of tissue for mice treated with 30 MBq of ¹⁷⁷Lu-PSMA-617 (5 mice per time point). Tabulated values and additional organs are available in supplemental materials. (B) Mean percentage injected activity of ¹⁷⁷Lu-PSMA-617 in tumors over time used for curve-fitting and dosimetry. Best-fit parameters are shown. (C) Mean ± SD percentage injected activity per gram of tissue for mice treated with 40 kBq of ²²⁵Ac-PSMA-617 (5 mice per time point). Tabulated values and additional organs are available in supplemental materials. (D) Mean percentage injected activity of ²²⁵Ac-PSMA-617 in tumors over time used for curve-fitting and dosimetry. Best-fit parameters are shown.




FIGURE 3. Therapeutic efficacy for mice treated 3 wk after inoculation with $^{177}Lu/^{225}Ac-PSMA-617$ or in tandem. (A) Mean \pm SD whole-body radiance over time (10 mice per group). Data are shown for time points with 5 or more remaining mice. (B) Individual mouse fold change in radiance over time relative to disease burden at time of treatment. NT = no treatment.

both as a single agent and in combination with ¹⁷⁷Lu-PSMA-617 was associated with significant tumor growth retardation (P = 0.009 for tandem vs. ¹⁷⁷Lu; P = 0.0084 for ²²⁵Ac vs. ¹⁷⁷Lu; P > 0.999 for tandem vs. ²²⁵Ac measured 5 wk after treatment). If mice were left untreated, median survival was 8.3 wk. When mice were treated with 35 MBq of ¹⁷⁷Lu-PSMA-617, no significant survival benefit was observed (median survival, 9.4 wk; P = 0.337). However, when treated with one of the ²²⁵Ac regimens, the median survival increased to 14.1 wk for the tandem approach and 15.3 wk for ²²⁵Ac-PSMA-617 alone (P < 0.0001 for tandem vs. ¹⁷⁷Lu; P < 0.0001 for ²²⁵Ac vs. ¹⁷⁷Lu; P = 0.108 for ²²⁵Ac vs. tandem).

When mice were treated at a later time point of macroscopic disease (5 wk after inoculation), all treatment groups showed retarded tumor growth relative to untreated mice (Fig. 5). However, the greatest benefits were observed with ²²⁵Ac-PSMA-617 monotherapy and tandem approaches (P < 0.0001 for ²²⁵Ac vs. ¹⁷⁷Lu; P < 0.0001 for tandem vs. ¹⁷⁷Lu measured 5 wk after treatment). Median overall survival increased from 7.9 wk (untreated) to 10.3 wk for ¹⁷⁷Lu-PSMA-617, 13.2 wk for tandem therapy, and 14.6 wk for ²²⁵Ac-PSMA-617 alone (P < 0.0001 for NT vs. ¹⁷⁷Lu; P < 0.0001 for




FIGURE 4. Survival curves for mice treated 3 wk after inoculation with ¹⁷⁷Lu/²²⁵Ac-PSMA-617 or in tandem. Median overall survival increased from 8.3 to 9.4 wk for ¹⁷⁷Lu-PSMA-617, 14.1 wk for tandem therapy, and 15.3 wk for ²²⁵Ac-PSMA-617 alone (P = 0.337 for NT vs. ¹⁷⁷Lu, P < 0.0001 for tandem vs. ¹⁷⁷Lu; P < 0.0001 for ²²⁵Ac vs. ¹⁷⁷Lu; P = 0.108 for ²²⁵Ac vs. tandem). NT = no treatment.

tandem vs. ¹⁷⁷Lu; P < 0.0001 for ²²⁵Ac vs. ¹⁷⁷Lu) (Fig. 6). There were no significant differences in whole-body disease burden or survival benefit conferred between ²²⁵Ac alone and halving the ²²⁵Ac activity in tandem with ¹⁷⁷Lu (P = 0.171 for ²²⁵Ac vs. tandem survival and P > 0.999 for ²²⁵Ac vs. tandem whole-body radiance 5 wk after treatment).

DISCUSSION

To our knowledge, this was the first study reporting on the efficacy of ¹⁷⁷Lu/²²⁵Ac-PSMA tandem-isotope combinations in a mouse model of prostate cancer. In this work, we sought to com-

pare the treatment efficacy of the same tumor dose delivered by 3 different radiation mechanisms: β -particles (¹⁷⁷Lu), α -particles (^{225}Ac) , or both $(^{177}Lu + ^{225}Ac)$. To do so, we first determined comparable injected activities to yield comparable tumor doses by conducting a full ex vivo biodistribution study using both ¹⁷⁷Lu-PSMA-617 and ²²⁵Ac-PSMA-617. It is important to note that the applied injected activities were chosen so as to expose the cancerous lesions to comparable absorbed radiation doses, without adjustment for the effectiveness of the type of radiation. Interestingly, there was no significant difference in peak tumor uptake of ¹⁷⁷Lu- or ²²⁵Ac-PSMA-617</sup> at 4h after injection; however, increased tumor retention was observed at all subsequent time points for mice treated with ²²⁵Ac-PSMA-617 compared with ¹⁷⁷Lu-PSMA-617. Although normal-organ biodistribution was not the primary objective of this report, all biodistribution data are available in the supplemental materials. In addition to the kidneys, liver, salivary glands, and intestines included in this report, uptake data for the following additional organs are available: blood, heart, lungs, spleen, stomach (with contents), prostate, testes, muscle, femur (with and without bone marrow), bone marrow, and brain.

In this work, we challenged a tandem-isotope approach against an advanced model of widespread disease to compare the dynamics of tumor control and overall survival. To more objectively compare the treatment arms against one another, we first determined injected activities for ¹⁷⁷Lu and ²²⁵Ac that expose the tumors to similar absorbed doses in the subcutaneous C4-2 model. We then designed the tandem arm to be a combination of half of each respective single-agent activity. The tandem-isotope approach was tested with the intracardiac inoculation model of C4-2 cells, at 2 different stages of disease progression with different volumes of lesions. Although subcutaneous tumors allow for straightforward uptake quantification, and therefore interrogation into absorbed doses, they fail to recapitulate the metastatic state. Dosimetry was not feasible in the intracardiac inoculation model because the lesions are not easily isolated, especially in microscopic stages. Translating dosimetry findings from subcutaneous models is one approach toward standardizing the applied activity when the tumor burden is distributed throughout the mouse and direct dosimetry is not possible. Furthermore, we sought to investigate the performance of tandem therapy in a model that more faithfully represents the setting in which treatment with α -particles (alone or in combination) would actually be clinically warranted.

The intracardiac inoculation model is an aggressive prostate cancer model in which mice, when left untreated, succumb to




FIGURE 5. Therapeutic efficacy for mice treated 5 wk after inoculation with $^{177}Lu/^{225}Ac-PSMA-617$ or in tandem. (A) Mean \pm SD whole-body radiance over time (10 mice per group). Data are shown for time points with 5 or more remaining mice. (B) Individual mouse fold change in radiance over time relative to disease burden at time of treatment. NT = no treatment.

extensive disseminated disease warranting euthanasia by 8 wk after inoculation (Figs. 4 and 6). This model has previously been shown to be sensitive to treatment with ²²⁵Ac-PSMA-617 early in the disease, but this work is the first effort, to our knowledge, at challenging at a very advanced stage (5 wk after inoculation) (41). By treating at 2 different stages of disease, we can also seek to answer what size lesions most benefit from treatment with ¹⁷⁷Lu or tandem approaches. At the onset of the earlier treatment time investigated (3 wk after inoculation), the disseminated lesions are approximately 200 µm in size, increasing to millimeter scale by 5 wk, as previously characterized (41). When given at 3 wk, ¹⁷⁷Lu-PSMA-617 as a single agent did not significantly improve tumor control or survival relative to untreated mice (Fig. 4). However, when lesions were millimeters in size at the time of treatment, ¹⁷⁷Lu-PSMA-617 retarded tumor growth and the mice conferred a significant survival advantage. Failure of ¹⁷⁷Lu-PSMA-617 against micron-scale lesions in the earlier treatment setting can be explained by a mismatch between the target lesion size and the pathlength of the therapeutic radiation. With a mean tissue range of 600 μ m (9), β -particles from ¹⁷⁷Lu travel a distance that




FIGURE 6. Survival curves for mice treated 5 wk after inoculation with ¹⁷⁷Lu/²²⁵Ac-PSMA-617 or in tandem. Median overall survival increased from 7.9 to 10.3 wk for ¹⁷⁷Lu-PSMA-617, 13.2 wk for tandem therapy, and 14.6 wk for ²²⁵Ac-PSMA-617 alone (P < 0.0001 for NT vs. ¹⁷⁷Lu; P < 0.0001 for Tandem vs. ¹⁷⁷Lu; P < 0.0001 for ²²⁵Ac vs. ¹⁷⁷Lu; P = 0.171 for ²²⁵Ac vs. tandem). NT = no treatment.

exceeds the lesion size at the time of early treatment (3 wk). This results in a loss of specificity to the targeted lesions and attenuates tumor response, as confirmed in this study.

Given the tissue range of less than 0.1 mm, α -particles from ²²⁵Ac yield dense ionizing paths with little to no cross-fire effect. For treatment at both stages of disease, mice treated with ²²⁵Ac-PSMA-617 as a single agent survived the longest and experienced the best tumor control (despite not reaching statistically significant differences at all time points). Even when challenged with lesions on the millimeter scale, the single agent ²²⁵Ac-PSMA-617</sup> outperformed ¹⁷⁷Lu-PSMA-617</sup>. Interestingly,

halving the ²²⁵Ac activity in tandem with ¹⁷⁷Lu did not significantly increase the whole-body disease burden as measured 5 wk after treatment (Figs. 3A and 5A). In this model, the comparable tumor control and survival between the full ²²⁵Ac dose and the tandem dose regimen suggest that a reduced administered activity of ²²⁵Ac could be adequately compensated with ¹⁷⁷Lu without significantly sacrificing effectiveness. The superior therapeutic efficacy of ²²⁵Ac in the microscopic setting studied in this work suggests a preference for α -emitters alone, or possibly in combination, for treatment of microscopic or minimal residual disease.

This work compares therapeutic isotopes using a fixed activity prescription for the tandem-isotope treatment arm. However, in the few published studies describing tandem treatment approaches of ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617 in the clinical setting, the applied injected activities have been heterogeneous. The mean reported activity of ¹⁷⁷Lu-PSMA-617 has ranged from 6 to 6.7 GBq, whereas the mean activity of ²²⁵Ac-PSMA-617 has ranged from 2.7 to 4 MBg (35,37). Another study reported a median ¹⁷⁷Lu-PSMA-617 activity of 6.9 GBq (ranging from 5.0 to 11.6 GBq) and 5.3 MBq (ranging from 1.5 to 7.9 MBq) for ²²⁵Ac-PSMA-617 (36). This wide range in applied activities precludes interpretation of a recommended activity scheme, and the heterogeneity underscores that, in practice, the treatment activities should reflect the individual patient condition. Additional studies are thereby needed to establish maximum tolerated doses in tandem-isotope schemes. One such prospective study examining the combination of ¹⁷⁷Lu-PSMA-I&T and ²²³Ra (AlphaBet trial NCT05383079) is under way using a fixed 7.4 GBq of ¹⁷⁷Lu-PSMA administration followed by escalating activities of ²²³Ra (48). Furthermore, prior treatments, including the cumulative injected activity of ¹⁷⁷Lu-PSMA-617 as a monotherapy if applicable, should also be considered in the activity prescription. Yet another factor to consider in the design of tandem-isotope treatments is the timing of the relative administrations. Although our preclinical work investigated the simultaneous administration of ¹⁷⁷Lu and ²²⁵Ac, tandem treatment on consecutive days or in the first few days of each cycle also warrants investigation. Further work is required to understand the optimal conditions under which to prescribe tandem-isotope approaches, including how to adapt the treatment activities to reflect individual patient tumor burden, metastatic extent, and prior treatments.

One limitation of the mouse models used in these studies is the inability to recapitulate critical organ uptake as seen in patients (i.e., in the salivary glands and kidneys). In the subcutaneous tumor model, kidney uptake was higher with ²²⁵Ac than with ¹⁷⁷Lu

at 1 h after injection; however, no significant difference was observed beyond the initial uptake phase. Clinically, kidney and salivary gland equivalent doses from ¹⁷⁷Lu-PSMA-617 were reported in one study as 0.39 and 0.36–0.58 Sv/GBq, respectively (*13*). For ²²⁵Ac-PSMA-617, one dosimetry report calculated kidney and salivary gland doses to be 0.74 and 2.33 Sv/MBq, respectively (assuming a relative biologic effectiveness factor of 5 for ²²⁵Ac) (*49*). However, our biodistribution study revealed no significant differences in submandibular gland uptake between ¹⁷⁷Lu- and ²²⁵Ac-treated mice, and peak uptake was less than 0.5% of injected activity at all measured time points (Fig. 2). Given this inherent limitation in the translatability of salivary gland toxicity, it was not within the scope of this study to assess the preclinical feasibility of tandem-isotope treatment to improve the toxicity profile.

CONCLUSION

Treatment of a microscopic model of prostate cancer with 40 kBq of ²²⁵Ac-PSMA-617 or 20 kBq of ²²⁵Ac in tandem with 17 MBq of ¹⁷⁷Lu resulted in significantly decreased tumor growth compared with ¹⁷⁷Lu, which was ineffective as a single agent against microscopic lesions, likely because of a mismatch of particle pathlength and lesion size. Mice treated later (when lesions were millimeter scale in size) experienced significant tumor growth retardation and survival benefit in both monotherapy and tandem regimes of ¹⁷⁷Lu- and ²²⁵Ac-PSMA therapy. However, the greatest benefits were observed with ²²⁵Ac-PSMA-617 as a single agent and in tandem approaches. Further work is needed to identify the disease patterns and settings that most benefit from treatment with β -particles, α -particles, or both.

DISCLOSURE

Katharina Lueckerath reports paid consulting activities for Sofie Biosciences/iTheranostics and funding from AMGEN outside the submitted work. Jeremie Calais reports prior consulting activities for Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, EXINI, IBA RadioPharma, Janssen Pharmaceuticals, Lantheus, POINT Biopharma, Progenics, Radiomedix, and Telix Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.

KEY POINTS

QUESTION: Does dual-isotope tandem ¹⁷⁷Lu/²²⁵Ac-PSMA radionuclide therapy improve treatment outcomes in a mouse model of disseminated prostate cancer?

PERTINENT FINDINGS: We determined equivalent tumor dose–depositing injected activities of ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617</sup> and tested treatment as single agents versus in combination against different-sized lesions. ²²⁵Ac alone, and in tandem with ¹⁷⁷Lu, was superior to ¹⁷⁷Lu as a single agent against microscopic lesions. No significant difference was observed between the tandem and ²²⁵Ac treatment arms.

IMPLICATIONS FOR PATIENT CARE: This work provides efficacy data for ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617 as single agents and in combination against lesions of micron to millimeter scale. These data can be used as a basis for further investigations into the disease conditions best suited for treatment with β -particles, α -particles, or both.

REFERENCES

- 1. Wong FC. MIRD: radionuclide data and decay schemes. J Nucl Med. 2009;50: 2091.
- Awang ZH, Essler M, Ahmadzadehfar H. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. *Radiat Oncol.* 2018;13:98.
- Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with ¹⁷⁷Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. *Clin Nucl Med.* 2016;41:522–528.
- Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with ¹⁷⁷Lu-labeled PSMA-617. *J Nucl Med.* 2016;57:1170–1176.
- Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating ¹⁷⁷Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. *J Nucl Med.* 2017;58:85–90.
- Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with ¹⁷⁷Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. *Oncotarget*. 2016;7:12477–12488.
- Hofman MS, Violet J, Hicks RJ, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. *Lancet Oncol.* 2018;19:825–833.
- Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. *J Med Radiat Sci.* 2017;64:52–60.
- Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. *Nat Rev Drug Discov.* 2020;19: 589–608.
- Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: α, β, or both? J Nucl Med. 2017;58:1017–1018.
- Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for ¹⁷⁷Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. *Eur J Nucl Med Mol Imaging.* 2016;43:42–51.
- Kabasakal L, AbuQbeitah M, Aygün A, et al. Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2015;42:1976–1983.
- Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. *J Nucl Med.* 2019;60:517–523.
- Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–328.
- Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl 1):1998–204S.
- Birindelli G, Drobnjakovic M, Morath V, et al. In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy. *Annu Int Conf IEEE Eng Med Biol Soc.* 2021;2021:4497–4500.
- Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. *Adv Drug Deliv Rev.* 2008;60:1371–1382.
- Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. *Curr Radiopharm*. 2011;4:306–320.
- McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. *Cell Death Differ*. 2002;9:593–594.
- Sathekge M, Bruchertseifer F, Knoesen O, et al. ²²⁵Ac-PSMA-617 in chemotherapynaive patients with advanced prostate cancer: a pilot study. *Eur J Nucl Med Mol Imaging*. 2019;46:129–138.
- Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. *Theranostics*. 2020;10:9364–9377.
- Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with ²²⁵Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. *J Nucl Med.* 2018; 59:795–802.
- Kratochwil C, Bruchertseifer F, Giesel FL, et al. ²²⁵Ac-PSMA-617 for PSMAtargeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. *J Nucl Med.* 2016;57:1941–1944.
- Kojima S, Cuttler JM, Shimura N, Koga H, Murata A, Kawashima A. Present and future prospects of radiation therapy using α-emitting nuclides. *Dose Response*. 2018;16:1559325817747387.
- Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with ²²⁵actinium and ²¹³bismuth. *Curr Radiopharm.* 2018;11:200–208.

- Chakravarty R, Siamof CM, Dash A, Cai W. Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. *Am J Nucl Med Mol Imaging*. 2018;8:247–267.
- van der Doelen MJ, Mehra N, van Oort IM, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with ²²⁵Ac-PSMA-617 targeted alpha-radiation therapy. *Urol Oncol.* 2021;39: 729.e7–729.e16.
- Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA-targeted radionuclide therapy: a review of the lessons learnt so far. *Nucl Med Biol.* 2021;98-99:30–39.
- Rupp NJ, Umbricht CA, Pizzuto DA, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for ⁶⁸Ga-PSMA-11 in salivary glands. *J Nucl Med.* 2019;60:1270–1276.
- Tönnesmann R, Meyer PT, Eder M, Baranski A-C. [¹⁷⁷Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography. *Pharmaceuticals (Basel)*. 2019;12:18.
- Roy J, Warner BM, Basuli F, et al. Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents. *Cancer Biother Radiopharm.* 2020;35:284–291.
- Taïeb D, Foletti JM, Bardies M, Rocchi P, Hicks RJ, Haberkorn U. PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter? *J Nucl Med.* 2018;59:747–748.
- Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. *Eur Urol.* 2021;79:343–350.
- Kratochwil C, Haberkom U, Giesel FL. ²²⁵Ac-PSMA-617 for therapy of prostate cancer. *Semin Nucl Med.* 2020;50:133–140.
- 35. Rosar F, Krause J, Bartholomä M, et al. Efficacy and safety of [²²⁵Ac]Ac-PSMA-617 augmented [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis. *Pharmaceutics*. 2021;13:722.
- Khreish F, Ebert N, Ries M, et al. ²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. *Eur J Nucl Med Mol Imaging*. 2020;47:721–728.
- 37. Rosar F, Hau F, Bartholomä M, et al. Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy. *Theranostics*. 2021;11:4050–4060.

- 38. Zemczak A, Kołodziej M, Gut P, et al. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [¹⁸F]FDG PET/CT qualification in Polish multicentre experience do we need [¹⁸F]FDG PET/CT for qualification to PRRT? *Endokrynol Pol.* 2020;71:240–248.
- Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using ⁹⁰Y/¹⁷⁷Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects: Polish multicenter experience. *Eur J Nucl Med Mol Imaging*. 2020;47:922–933.
- de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. *J Nucl Med.* 2005;46(suppl 1):13S–17S.
- Stuparu AD, Meyer CAL, Evans-Axelsson SL, et al. Targeted alpha therapy in a systemic mouse model of prostate cancer: a feasibility study. *Theranostics*. 2020; 10:2612–2620.
- Fendler WP, Stuparu AD, Evans-Axelsson S, et al. Establishing ¹⁷⁷Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. *J Nucl Med.* 2017;58:1786–1792.
- Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of resistance to prostatespecific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 2021;62:989–995.
- Kruijff RM, Raavé R, Kip A, et al. The in vivo fate of ²²⁵Ac daughter nuclides using polymersomes as a model carrier. *Sci Rep.* 2019;9:11671.
- Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. *Med Phys.* 2013; 40:102504.
- Jiang Z, Revskaya E, Fisher DR, Dadachova E. In vivo evaluation of free and chelated accelerator-produced actinium-225: radiation dosimetry and toxicity results. *Curr Radiopharm.* 2018;11:215–222.
- Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. *Lab Anim Sci.* 1999;49:319–323.
- Combination of radium-223 and lutetium-177 PSMA-I&T in men with metastatic castration-resistant prostate cancer. ClinicalTrials.gov website. https://ClinicalTrials. gov/show/NCT05383079. Updated September 28, 2022. Accessed August 22. 2023.
- Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with ²²⁵Ac-PSMA-617: dosimetry estimate and empiric dose finding. *J Nucl Med.* 2017;58:1624–1631.